Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CORCEPT THERAPEUTICS INCCORT · Entity 2620 | See Remarks | October 01, 2026 | October 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CORCEPT THERAPEUTICS INC
Report date October 01, 2026 · Filed October 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,938 |
Last balance in matching sequence
After 2026-10-02 transaction · row 5
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
5 source rowsRow 1 · 2026-10-01 · Exercise / conversion · Acquired 413 · Balance 10,351 F1: Includes 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 150 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Row 2 · 2026-10-01 · Sale · Disposed 413 · Balance 9,938 F2: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction. F3: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.30 to $115.615 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F1: Includes 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 150 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Row 3 · 2026-10-02 · Exercise / conversion · Acquired 24,587 · Balance 34,525 F1: Includes 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 150 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Row 4 · 2026-10-02 · Sale · Disposed 15,843 · Balance 18,682 F2: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction. F4: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.38 to $116.36 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F1: Includes 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 150 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Row 5 · 2026-10-02 · Sale · Disposed 8,744 · Balance 9,938 F2: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction. F5: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $116.39 to $117.22 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F1: Includes 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 150 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.27 · Expires 2027-02-10 | Direct | 66,573 |
Reported balance
After 2026-10-01 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-10-01 · Exercise / conversion · Disposed 413 · Balance 66,573 F11: Fully exercisable. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.27 · Expires 2027-02-10 | Direct | 41,986 |
Reported balance
After 2026-10-02 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-10-02 · Exercise / conversion · Disposed 24,587 · Balance 41,986 F11: Fully exercisable. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 5,147 |
Reported balance
Holding disclosure · report date 2026-10-01 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 5,147 F6: Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 20,570 |
Reported balance
Holding disclosure · report date 2026-10-01 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 20,570 F7: Represents the shares held by MMM 2025, LLC of which the Reporting Person is a member and manager. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 40,000 |
Reported balance
Holding disclosure · report date 2026-10-01 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 40,000 F8: Represents the shares held by SNM 2025 Grantor Retained Annuity Trust of which the Reporting Person is the trustee. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 34,000 |
Reported balance
Holding disclosure · report date 2026-10-01 · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · Balance 34,000 F9: Represents the shares held by SNM 2026 Grantor Retained Annuity Trust of which the Reporting Person is the trustee. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 10,000 |
Reported balance
Holding disclosure · report date 2026-10-01 · row 10
Holding and transaction disclosures are not merged.
1 source rowRow 10 · Balance 10,000 F10: Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 150 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F2: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction.
F3: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.30 to $115.615 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F4: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.38 to $116.36 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F5: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $116.39 to $117.22 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F6: Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee.
F7: Represents the shares held by MMM 2025, LLC of which the Reporting Person is a member and manager.
F8: Represents the shares held by SNM 2025 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
F9: Represents the shares held by SNM 2026 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
F10: Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
F11: Fully exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2023 Filed Jun 3, 2025 00:57 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 1,059 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-080528 · ownership.xml · nonDerivative · entry 17 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,929 F1 · balance_after: Includes 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| July 17, 2023 Filed Jul 19, 2023 20:30 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 10,000 | $0.00 Strike: $1.92 | $0.00 |
DisclosureSEC source: 0000950170-23-033534 · ownership.xml · derivative · entry 4 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2023-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully exercisable. Read SEC document |
| July 17, 2023 Filed Jul 19, 2023 20:30 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 10,000 | $1.92 | $19,200.00 |
DisclosureSEC source: 0000950170-23-033534 · ownership.xml · nonDerivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,698 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 922 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022, 1,460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, and 1,658 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| July 17, 2023 Filed Jun 3, 2025 00:57 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | OtherCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-080528 · ownership.xml · nonDerivative · entry 16 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 68,634 F2 · kind: Transfer of shares without consideration to the Sean and Molly Maduck Living Trust. F3 · ownership.nature: Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee. Read SEC document |
| July 17, 2023 Filed Jun 3, 2025 00:57 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-080528 · ownership.xml · nonDerivative · entry 15 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,988 F1 · balance_after: Includes 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 23:01 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 1,658 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-014510 · doc4.xml · nonDerivative · entry 2 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,698 F4 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. F3 · balance_after: Includes 922 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022, and 1,460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 23:01 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 1,658 | $22.97 | $38,084.26 |
DisclosureSEC source: 0000899243-23-014510 · doc4.xml · nonDerivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,040 F1 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2012 Incentive Award Plan on June 1, 2023. F2 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. F3 · balance_after: Includes 922 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022, and 1,460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| June 01, 2023 Filed Jun 3, 2025 00:57 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | OtherCommon Stock | 1,658 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-080528 · ownership.xml · nonDerivative · entry 14 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 58,634 F2 · kind: Transfer of shares without consideration to the Sean and Molly Maduck Living Trust. F3 · ownership.nature: Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee. Read SEC document |
| June 01, 2023 Filed Jun 3, 2025 00:57 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 1,658 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-080528 · ownership.xml · nonDerivative · entry 13 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,988 F1 · balance_after: Includes 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 23:54 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 1,460 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-007055 · doc4.xml · nonDerivative · entry 2 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,382 F4 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. F3 · balance_after: Includes 922 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 23:54 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 1,460 | $19.86 | $28,995.60 |
DisclosureSEC source: 0000899243-23-007055 · doc4.xml · nonDerivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,922 F1 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2012 Incentive Award Plan on March 1, 2023. F2 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. F3 · balance_after: Includes 922 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 01, 2023 Filed Jun 3, 2025 00:57 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | OtherCommon Stock | 1,460 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-080528 · ownership.xml · nonDerivative · entry 12 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 56,976 F2 · kind: Transfer of shares without consideration to the Sean and Molly Maduck Living Trust. F3 · ownership.nature: Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee. Read SEC document |
| March 01, 2023 Filed Jun 3, 2025 00:57 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 1,460 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-080528 · ownership.xml · nonDerivative · entry 11 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,646 F1 · balance_after: Includes 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| February 13, 2023 Filed Feb 16, 2023 00:58 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock option (right to buy) · Derivative | 200,000 | $0.00 Strike: $23.06 | $0.00 |
DisclosureSEC source: 0000899243-23-005172 · doc4.xml · derivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2033-02-12 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of February 13, 2023 over a four-year period. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 21:45 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 625 | $0.00 Strike: $3.29 | $0.00 |
DisclosureSEC source: 0000899243-22-037636 · doc4.xml · derivative · entry 5 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,977 Underlying: Common Stock · 625 shares Expires 2025-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully exercisable. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 21:45 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 625 | $25.28 | $15,800.00 |
DisclosureSEC source: 0000899243-22-037636 · doc4.xml · nonDerivative · entry 2 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,462 F1 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. F2 · balance_after: Includes 922 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 21:45 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 625 | $3.29 | $2,056.25 |
DisclosureSEC source: 0000899243-22-037636 · doc4.xml · nonDerivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,087 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · balance_after: Includes 922 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| November 10, 2022 Filed Nov 15, 2022 21:45 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 25,000 | $0.00 Strike: $3.29 | $0.00 |
DisclosureSEC source: 0000899243-22-035882 · doc4.xml · derivative · entry 5 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,602 Underlying: Common Stock · 25,000 shares Expires 2025-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully exercisable. Read SEC document |
| November 10, 2022 Filed Nov 15, 2022 21:45 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 25,000 | $25.57 | $639,250.00 |
DisclosureSEC source: 0000899243-22-035882 · doc4.xml · nonDerivative · entry 2 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,462 F1 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $25.55 to $25.65. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. F2 · balance_after: Includes 922 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| November 10, 2022 Filed Nov 15, 2022 21:45 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 25,000 | $3.29 | $82,250.00 |
DisclosureSEC source: 0000899243-22-035882 · doc4.xml · nonDerivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,462 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · balance_after: Includes 922 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| October 03, 2022 Filed Oct 4, 2022 21:30 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 25,000 | $0.00 Strike: $3.29 | $0.00 |
DisclosureSEC source: 0000899243-22-032731 · doc4.xml · derivative · entry 5 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,602 Underlying: Common Stock · 25,000 shares Expires 2025-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully exercisable. Read SEC document |
| October 03, 2022 Filed Oct 4, 2022 21:30 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 25,000 | $25.64 | $641,000.00 |
DisclosureSEC source: 0000899243-22-032731 · doc4.xml · nonDerivative · entry 2 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,462 F1 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $25.64 to $25.66. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. F2 · balance_after: Includes 922 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| October 03, 2022 Filed Oct 4, 2022 21:30 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 25,000 | $3.29 | $82,250.00 |
DisclosureSEC source: 0000899243-22-032731 · doc4.xml · nonDerivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,462 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · balance_after: Includes 922 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| September 01, 2022 Filed Sep 7, 2022 00:50 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 25,000 | $0.00 Strike: $3.29 | $0.00 |
DisclosureSEC source: 0000899243-22-030515 · doc4.xml · derivative · entry 7 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,602 Underlying: Common Stock · 15,000 shares Expires 2025-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Fully exercisable. Read SEC document |
| September 01, 2022 Filed Sep 7, 2022 00:50 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 922 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-030515 · doc4.xml · nonDerivative · entry 4 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,462 F5 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements under the Purchase Plan. Read SEC document |
| September 01, 2022 Filed Sep 7, 2022 00:50 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 922 | $25.98 | $23,953.56 |
DisclosureSEC source: 0000899243-22-030515 · doc4.xml · nonDerivative · entry 3 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,540 F3 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2012 Incentive Award Plan on September 1, 2022. F4 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. Read SEC document |
| September 01, 2022 Filed Sep 7, 2022 00:50 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 25,000 | $25.84 | $646,000.00 |
DisclosureSEC source: 0000899243-22-030515 · doc4.xml · nonDerivative · entry 2 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,618 F1 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $25.82 to $25.94. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. Read SEC document |
| September 01, 2022 Filed Sep 7, 2022 00:50 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 25,000 | $3.29 | $82,250.00 |
DisclosureSEC source: 0000899243-22-030515 · doc4.xml · nonDerivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,618 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2022 Filed Jun 3, 2025 00:57 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | OtherCommon Stock | 922 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-080528 · ownership.xml · nonDerivative · entry 10 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 55,516 F2 · kind: Transfer of shares without consideration to the Sean and Molly Maduck Living Trust. F3 · ownership.nature: Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee. Read SEC document |
| September 01, 2022 Filed Jun 3, 2025 00:57 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 922 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-080528 · ownership.xml · nonDerivative · entry 9 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,106 F1 · balance_after: Includes 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| August 19, 2022 Filed Aug 22, 2022 23:32 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 15,000 | $0.00 Strike: $2.24 | $0.00 |
DisclosureSEC source: 0000899243-22-029492 · doc4.xml · derivative · entry 5 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2022-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully exercisable. Read SEC document |
| August 19, 2022 Filed Aug 22, 2022 23:32 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Tax withholdingCommon Stock | 406 | $27.60 | $11,205.60 |
DisclosureSEC source: 0000899243-22-029492 · doc4.xml · nonDerivative · entry 2 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,618 F1 · kind: These shares were withheld so the Reporting Person could satisfy the exercise price arising from a net (cashless) exercise of stock options that occurred on August 19, 2022. The options subject to the net exercise were to expire on November 1, 2022. Read SEC document |
| August 19, 2022 Filed Aug 22, 2022 23:32 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 15,000 | $2.24 | $33,600.00 |
DisclosureSEC source: 0000899243-22-029492 · doc4.xml · nonDerivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 19, 2022 Filed Jun 3, 2025 00:57 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | OtherCommon Stock | 14,594 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-080528 · ownership.xml · nonDerivative · entry 8 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 54,594 F2 · kind: Transfer of shares without consideration to the Sean and Molly Maduck Living Trust. F3 · ownership.nature: Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee. Read SEC document |
| August 19, 2022 Filed Jun 3, 2025 00:57 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 14,594 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-080528 · ownership.xml · nonDerivative · entry 7 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,028 F1 · balance_after: Includes 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| August 12, 2022 Filed Aug 16, 2022 21:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 15,000 | $0.00 Strike: $3.29 | $0.00 |
DisclosureSEC source: 0000899243-22-028828 · doc4.xml · derivative · entry 7 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,059 Underlying: Common Stock · 15,000 shares Expires 2025-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully exercisable. Read SEC document |
| August 12, 2022 Filed Aug 16, 2022 21:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 9,800 | $0.00 Strike: $1.92 | $0.00 |
DisclosureSEC source: 0000899243-22-028828 · doc4.xml · derivative · entry 6 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 9,800 shares Expires 2023-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully exercisable. Read SEC document |
| August 12, 2022 Filed Aug 16, 2022 21:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 24,800 | $28.70 | $711,760.00 |
DisclosureSEC source: 0000899243-22-028828 · doc4.xml · nonDerivative · entry 3 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $28.70 to $28.76. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. Read SEC document |
| August 12, 2022 Filed Aug 16, 2022 21:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 15,000 | $3.29 | $49,350.00 |
DisclosureSEC source: 0000899243-22-028828 · doc4.xml · nonDerivative · entry 2 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,824 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. Read SEC document |
| August 12, 2022 Filed Aug 16, 2022 21:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 9,800 | $1.92 | $18,816.00 |
DisclosureSEC source: 0000899243-22-028828 · doc4.xml · nonDerivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,824 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. Read SEC document |
| August 09, 2022 Filed Aug 11, 2022 21:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 200 | $0.00 Strike: $1.92 | $0.00 |
DisclosureSEC source: 0000899243-22-028396 · doc4.xml · derivative · entry 5 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,800 Underlying: Common Stock · 200 shares Expires 2023-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully exercisable. Read SEC document |
| August 09, 2022 Filed Aug 11, 2022 21:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 200 | $28.70 | $5,740.00 |
DisclosureSEC source: 0000899243-22-028396 · doc4.xml · nonDerivative · entry 2 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,024 F1 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. Read SEC document |
| August 09, 2022 Filed Aug 11, 2022 21:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 200 | $1.92 | $384.00 |
DisclosureSEC source: 0000899243-22-028396 · doc4.xml · nonDerivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,224 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. Read SEC document |
| July 18, 2022 Filed Jul 20, 2022 00:30 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 5,000 | $0.00 Strike: $1.92 | $0.00 |
DisclosureSEC source: 0000899243-22-026384 · doc4.xml · derivative · entry 7 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 5,000 shares Expires 2023-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully exercisable. Read SEC document |
| July 18, 2022 Filed Jul 20, 2022 00:30 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000899243-22-026384 · doc4.xml · derivative · entry 6 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2023-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully exercisable. Read SEC document |
| July 18, 2022 Filed Jul 20, 2022 00:30 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 25,000 | $27.37 | $684,250.00 |
DisclosureSEC source: 0000899243-22-026384 · doc4.xml · nonDerivative · entry 3 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,024 F1 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $27.24 to $27.51. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. Read SEC document |
| July 18, 2022 Filed Jul 20, 2022 00:30 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 5,000 | $1.92 | $9,600.00 |
DisclosureSEC source: 0000899243-22-026384 · doc4.xml · nonDerivative · entry 2 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. Read SEC document |
| July 18, 2022 Filed Jul 20, 2022 00:30 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 20,000 | $2.08 | $41,600.00 |
DisclosureSEC source: 0000899243-22-026384 · doc4.xml · nonDerivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. Read SEC document |
| May 02, 2022 Filed May 4, 2022 20:12 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $22.05 | $0.00 |
DisclosureSEC source: 0000899243-22-016594 · doc4.xml · derivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-05-01 F1 · derivative.exercise_date: Shares subject to this stock option vest and become exercisable at the rate of 1/48th of the total number of shares on each monthly anniversary of April 6, 2022, so that the total number of shares subject to this option becomes fully vested and exercisable on April 6, 2026, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| February 02, 2022 Filed Feb 12, 2022 00:20 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $19.26 | $0.00 |
DisclosureSEC source: 0000899243-22-005963 · doc4.xml · derivative · entry 1 Maduck Sean · CIK 0001698310 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2032-02-01 F1 · derivative.exercise_date: Shares subject to this stock option vest and become exercisable at the rate of 1/48th of the total number of shares on each monthly anniversary of February 2, 2022, so that the total number of shares subject to this option becomes fully vested and exercisable on February 2, 2026. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.